Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study

References

• Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009;145:379–82
   PubMed Web of Science ®Google Scholar
• Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–35
   PubMed Web of Science ®Google Scholar
• Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31:1000–6
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735–41
   PubMed Web of Science ®Google Scholar
• Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27:12–29
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2:e000062
   PubMed Web of Science ®Google Scholar
• Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68–73
   PubMed Web of Science ®Google Scholar
• Love TJ, Qureshi AA, Karlson EW, et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011;147:419–24
   PubMed Web of Science ®Google Scholar
• Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132:556–62
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013;68:654–62
   PubMed Web of Science ®Google Scholar
• Vanaclocha F, Belinchón I, Sánchez-Carazo JL, et al. Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-risk, descriptive study. Eur J Dermatol 2014 [Epub ahead of print]. doi:10.1684/ejd.2014.2440
   Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5
   PubMed Web of Science ®Google Scholar
• Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321–8
   PubMed Web of Science ®Google Scholar
• Miller IM, Ellervik C, Yazdanyar S, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69:1014–24
   PubMed Web of Science ®Google Scholar
• Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol. 2010;24:23–30
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149:84–91
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31:433–42
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2:e54
   PubMed Web of Science ®Google Scholar
• Guallar-Castillón P, Pérez RF, López García E, et al. Magnitude and management of metabolic syndrome in Spain in 2008–2010: the ENRICA Study. Rev Esp Cardiol. 2014;67:367–73
   PubMed Web of Science ®Google Scholar
• Fernández-Bergés D, Cabrera de León A, Sanz H, et al. Metabolic syndrome in Spain: prevalence and coronary risk associated with harmonized definition and WHO proposal. DARIOS study. Rev Esp Cardiol (Engl Ed). 2012;65:241–8
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–16
   PubMed Web of Science ®Google Scholar
• Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145:700–3
   PubMed Web of Science ®Google Scholar
• Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124:775.e1–6
   PubMed Web of Science ®Google Scholar
• Mattsson N, Rönnemaa T, Juonala M, et al. Arterial structure and function in young adults with the metabolic syndrome: the Cardiovascular Risk in Young Finns Study. Eur Heart J. 2008;29:784–91
   PubMed Web of Science ®Google Scholar
• Kondo T, Osugi S, Shimokata K, et al. Metabolic syndrome and all-cause mortality, cardiac events, and cardiovascular events: a follow-up study in 25,471 young- and middle-aged Japanese men. Eur J Cardiovasc Prev Rehabil. 2011;18:574–80
   PubMed Web of Science ®Google Scholar
• Kimball AB, Szapary P, Mrowietz U, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;67:76–85
   PubMed Web of Science ®Google Scholar
• Belinchon I, Vanaclocha F, Jimenez-Puya R, et al. Underdiagnosis of cardiovascular risk factors in patients with psoriasis under systemic therapy in Spain. Pso-risk study [abstract no. P082]. J Eur Acad Dermatol Venereol. 2013;27:35
   Web of Science ®Google Scholar
• Puig L, Strohal R, Husni ME, et al. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. J Dermatolog Treat. 2013. [Epub ahead of print]
   Google Scholar
• Carretero G, Ribera M, Belinchón I; Psoriasis Group of the AEDV. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104:598–616
   PubMedGoogle Scholar
• Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;(1):CD007893
   PubMedGoogle Scholar
• Puig L. Anti-tumour necrosis factor-α treatment and weight gain in psoriasis: the ‘pudgy blanching' conundrum. Br J Dermatol. 2013;168:923–4
   PubMed Web of Science ®Google Scholar
• Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors. Am J Clin Dermatol. 2014;15:45–50
   PubMed Web of Science ®Google Scholar
• Nguyen T, Wu JJ. Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review. Perm J. 2014;18:49–54
   PubMedGoogle Scholar
• Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014;105:31–44
   PubMedGoogle Scholar